{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:40:56Z","timestamp":1790516456515,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":1343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1111\/jth.14380","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T15:32:41Z","timestamp":1546961561000},"page":"460-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Administration of recombinant FVIIa (rFVIIa) to concizumab\u2010dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits"],"prefix":"10.1016","volume":"17","author":[{"given":"Brian","family":"Lauritzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Olling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin L.","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Augustsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Balling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Bjelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Charlotte","family":"Hegelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Hilden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14380_bb0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14380_bb0015","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia\u00a0A patients treated with plasma\u2010derived or recombinant factor\u00a0VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14380_bb0020","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH14-10-0826","article-title":"Inhibitor development in haemophilia according to concentrate. Four\u2010year results from the European HAemophilia Safety Surveillance (EUHASS) project","volume":"113","author":"Fischer","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14380_bb0025","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor\u00a0VIII and neutralizing antibodies in hemophilia\u00a0A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14380_bb0030","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/hae.12074","article-title":"Treatment Guidelines Working Group. The World Federation of Hemophilia. Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14380_bb0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.thromres.2013.12.015","article-title":"Target\u2010mediated clearance and bio\u2010distribution of a monoclonal antibody against the Kunitz\u2010type protease inhibitor\u00a02 domain of tissue factor pathway inhibitor","volume":"133","author":"Hansen","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14380_bb0040","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb\u00a02021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.14380_bb0045","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1074\/jbc.273.8.4378","article-title":"Regulation of extrinsic pathway factor\u00a0Xa formation by tissue factor pathway inhibitor","volume":"273","author":"Baugh","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.14380_bb0050","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood.V66.1.204.204","article-title":"Inhibition of tissue factor\/factor\u00a0VIIa activity in plasma requires factor\u00a0X and an additional plasma component","volume":"66","author":"Sanders","year":"1985","journal-title":"Blood"},{"key":"10.1111\/jth.14380_bb0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti\u2010TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14380_bb0060","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti\u2010tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14380_bb0065","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"Safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia\u00a0A: a phase\u00a01b, randomized trial","volume":"16","author":"Eichler","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14380_bb0070","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia\u00a0A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14380_bb0075","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1182\/blood-2014-05-576892","article-title":"In\u00a0vitro evidence of a tissue factor\u2010independent mode of action of recombinant factor\u00a0VIIa in hemophilia","volume":"124","author":"Augustsson","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.14380_bb0080","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1365-2516.2010.02333.x","article-title":"Functional characteristics of N8, a new recombinant FVIII","volume":"16","author":"Christiansen","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14380_bb0085","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood.V128.22.1401.1401","article-title":"Concizumab promotes hemostasis via a TF\u2010FVIIa dependent mechanism as shown in a rabbit hemophilia bleeding model","volume":"128","author":"Lauritzen","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.14380_bb0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2001-16890","article-title":"Recombinant activated factor\u00a0VII (rFVIIa): characterization, manufacturing, and clinical development","volume":"27","author":"Jurlander","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.14380_bb0095","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high\u2010dose factor\u00a0VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14380_bb0100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jth.13244","article-title":"Pharmacological concentrations of recombinant factor\u00a0VIIa restore hemostasis independent of tissue factor in antibody\u2010induced hemophilia mice","volume":"14","author":"Keshava","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14380_bb0105","unstructured":"Lauritzen B, Tranholm M, Ezban M, eds. A glycoPEGylated long acting rFVIIa reduces bleeding in hemophilic rabbits. Congress of the International Society on Thrombosis and Haemostasis (ISTH 2009); 2009. 11\u201316 July 2009: International Society on Thrombosis and Haemostasis."},{"key":"10.1111\/jth.14380_bb0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejps.2014.02.009","article-title":"Pharmacokinetics of an anti\u2010TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration","volume":"56","author":"Agers\u00f8","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1111\/jth.14380_bb0115","series-title":"Summary of Product Characteristics","year":"2017"},{"key":"10.1111\/jth.14380_bb0120","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first\u2010in\u2010human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF\u201006741086, an anti\u2010tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/jth.14380_bb0125","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0268-960X(15)30006-0","article-title":"Safety update on the use of recombinant activated factor\u00a0VII in approved indications","volume":"29","author":"Neufeld","year":"2015","journal-title":"Blood Rev"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362202829X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362202829X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.14380\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:23:23Z","timestamp":1761535403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362202829X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S153878362202829X"],"URL":"https:\/\/doi.org\/10.1111\/jth.14380","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Administration of recombinant FVIIa (rFVIIa) to concizumab\u2010dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}